<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02501031</url>
  </required_header>
  <id_info>
    <org_study_id>CBCF 2014-grant</org_study_id>
    <nct_id>NCT02501031</nct_id>
  </id_info>
  <brief_title>Flaxseed Intervention Study to Assess Sex Hormone Levels Among Post-Menopausal Women</brief_title>
  <official_title>Effect of Dietary Flaxseed on Circulating Sex Hormone Levels Among Post-menopausal Women - an Intervention Trial to Explore Flaxseed Intake as a Possible Breast Cancer Prevention Strategy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Care Ontario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Breast Cancer Foundation, Ontario Region (funder)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>York University, Institute for Social Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mount Sinai Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Care Ontario</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand whether consuming flaxseed for approximately 50&#xD;
      days may beneficially affect the level of certain hormones in the blood thought to be&#xD;
      involved in the development of breast cancer. This study will address the first steps toward&#xD;
      the development of possible breast cancer prevention strategies. Differences in hormone&#xD;
      levels (from blood samples) will be compared between two groups of women - those in the group&#xD;
      assigned to eating ground flaxseed daily and those in the control group (with no change in&#xD;
      diet).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate whether a dietary flaxseed intervention among post-menopausal women influences&#xD;
      circulating levels of sex steroid hormones and estrogen metabolites (including estradiol,&#xD;
      estrone, 2-hydroxy(OH)-/16-OH-estrone ratio, SHBG, testosterone, 2-MeOH-E1&amp;-E2,&#xD;
      4-MeOH-E1&amp;-E2) thought to be involved in the development of breast cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      II. Assess a) the effect of flaxseed intake on serum enterolignan levels (lignan biomarker),&#xD;
      b) the relationship between serum enterolignan and sex hormone levels.&#xD;
&#xD;
      III. Describe adherence to the flaxseed intervention.&#xD;
&#xD;
      OUTLINE: Participants are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM 1: Participants take 2 tablespoons of ground flaxseed daily for approximately 50 days.&#xD;
&#xD;
      ARM 2: Participants maintain their usual diet for approximately 50 days.&#xD;
&#xD;
      All participants will complete a questionnaire and have their blood drawn at the beginning of&#xD;
      the study (Day 0) and at the end of the study period (approximately Day 50).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in circulating levels of sex steroid hormones at Day 0 (baseline) compared with ~Day 50 (end of study period)</measure>
    <time_frame>Day 0 and ~Day 50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum enterolignan levels at Day 0 (baseline) compared with ~Day 50 (end of study period)</measure>
    <time_frame>Day 0 and ~Day 50</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Flaxseed (ground)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual diet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ground flaxseed</intervention_name>
    <description>2 tablespoons of ground flaxseed taken daily for approximately 50 days.</description>
    <arm_group_label>Flaxseed (ground)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Women residing in Toronto aged 57-64 years old, and post-menopausal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Consumers of flaxseed and soy (including supplements) in the past 6 months.&#xD;
&#xD;
          2. Consumers of sesame oil and sesame seeds in the past 6 months.&#xD;
&#xD;
          3. Women who took antibiotics orally in the past 6 months.&#xD;
&#xD;
          4. Women who took hormone replacement therapy or corticosteroids in the past month.&#xD;
&#xD;
          5. Non-English speaking.&#xD;
&#xD;
          6. Current chronic illnesses such as bowel disease (e.g. IBS - irritable bowel syndrome,&#xD;
             or IBD - inflammatory bowel disease, such as Crohn's or ulcerative colitis), diabetes,&#xD;
             heart disease (e.g. high cholesterol or high blood pressure and on medication for it),&#xD;
             cancer, or another chronic illness.&#xD;
&#xD;
          7. Women who are currently taking blood thinners, such as Warfarin.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>57 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Cotterchio, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Care Ontario and Dalla Lana School of Public Health, University of Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Care Ontario</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Flaxseed</keyword>
  <keyword>Postmenopause</keyword>
  <keyword>Hormones</keyword>
  <keyword>Lignans</keyword>
  <keyword>No Evidence of Disease</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

